ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases

  1. Tripathy, D.
  2. Tolaney, S.M.
  3. Seidman, A.D.
  4. Anders, C.K.
  5. Ibrahim, N.
  6. Rugo, H.S.
  7. Twelves, C.
  8. Dieras, V.
  9. Müller, V.
  10. Tagliaferri, M.
  11. Hannah, A.L.
  12. Cortés, J.
Revue:
Future Oncology

ISSN: 1744-8301,  1479-6694

Année de publication: 2019

Volumen: 15

Número: 19

Pages: 2211-2225

Type: Article

DOI: 10.2217/FON-2019-0180 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus